Pioneering a new category of oral therapies based on defined bacterial consortia
Pioneering a new category of oral therapies based on defined bacterial consortia
Description
Puretech Ownership1
Stage of Development
Pioneering a new category of oral therapies based on defined bacterial consortia
41% Equity
PHASE 3 READY
Description
Pioneering a new category of oral therapies based on defined bacterial consortia
Puretech Ownership1
41% Equity
Stage of Development
PHASE 3 READY
1As of June 30, 2023, PureTech’s percentage ownership of Vedanta Biosciences was approximately 41% on a partially diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans. Vedanta’s $106.5 million recent financing round was structured as convertible debt. PureTech ownership reflects current ownership and does not take into account any potential future dilution, if applicable, as a result of conversion of that debt amount.

Pioneering a new category of oral therapies based on defined bacterial consortia

Vedanta is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal banks. Vedanta is a leader in the field with capabilities and deep expertise to discover, develop and manufacture live bacteria-based therapies.
  • Program Discovery Process by the PureTech Team
    • We engaged with leading world-renowned experts in immunology and identified and in-licensed intellectual property to pioneer the concept of therapeutically defined consortia of microbes that could modulate the immune system or treat bacterial infections.
  • Milestones Achieved & Developmental Status
  • Expected Milestones
Note: Active INDs or the foreign regulatory equivalent are on file for VE202, VE303, VE416 and VE800. Our board designees represent a majority of the members of the board of directors of Vedanta, but Vedanta has its own independent management team. Our role in the development of Vedanta’s therapeutic candidates is through our representation on its board of directors and our role as a substantial shareholder. Vedanta intellectual property portfolio is believed to provide a dominant position for the development and commercialization of microbiome medicines based on defined consortia of gut bacteria. Vedanta was incorporated in December 2010.
5 As of December 31, 2022, PureTech’s percentage ownership of Vedanta Biosciences was approximately 40.8% on a partially diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans. Vedanta’s $106.5 million recent financing round was structured as convertible debt. PureTech ownership reflects current ownership and does not take into account any potential future dilution, if applicable, as a result of conversion of that debt amount.
Unlike fecal transplants, which require use of donors and are untargeted, inherently variable procedures, Vedanta’s approach is based on bacterial consortia therapeutics, which are defined drug compositions produced from clonally isolated bacteria that can trigger targeted immune responses. Unlike single strain probiotics, defined consortia can robustly shift the composition of the gut microbiota and provide colonization resistance against a range of intestinal infectious pathogens.

Press Releases